Picture of doctor speaking to patient
Incorporating SHINGRIX into your practice

Incorporating SHINGRIX into your practice involves proper administration, discussing disease risk and vaccination, and ensuring series completion.

Dosing and administration

SHINGRIX is a non-live, recombinant vaccine that is indicated for the prevention of shingles in adults ≥50 years old and in adults 18 years of age or older who are or will be at increased risk of HZ due to immunodeficiency or immunosuppression caused by known disease or therapy.1

Refer to the Product Monograph for complete dosing and administration information.

Counselling your patients on shingles vaccination

Ensuring series completion

* The SHINGRIX.ca web page is open to the general public.

Co-administration of SHINGRIX with other vaccines1

SHINGRIX can be given concomitantly with the following vaccines:

  • Unadjuvanted seasonal influenza vaccine
  • 23-valent pneumococcal polysaccharide vaccine (PPV23)
  • Fever and shivering were more frequent when PPV23 vaccine was co-administered with SHINGRIX
  • Reduced antigen diphtheria-tetanus-acellular pertussis vaccine (Tdap) 

The vaccines should be administered at different injection sites.

View reconstitution instructions for SHINGRIX

You and your office staff can learn how to administer SHINGRIX step by step.


  1. SHINGRIX Product Monograph. GlaxoSmithKline Inc., November 15, 2022.
  2. Harpaz R, Ortega-Sanchez IR, Seward JF; Advisory Committee on Immunization Practices (ACIP), Centers for Disease Control and Prevention (CDC). Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2008;57(RR-5):1-30.
  3. Government of Canada. Canadian Immunization Guide: Part 4 – Active Vaccines. Available at: https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/page-8-herpes-zoster-(shingles)-vaccine.html. Accessed March 5, 2018.
  4. Public Health Agency of Canada. An Advisory Committee Statement (ACS), National Advisory Committee on Immunization (NACI) – Updated Recommendations on the Use of Herpes Zoster Vaccines. Ottawa, Ontario: Public Health Agency of Canada; June 2018. Available at: https://www.canada.ca/en/services/health/publications/healthy-living/updated-recommendations-use-herpes-zoster-vaccines.html. Accessed November 30, 2022.

Trademarks are owned by or licensed to the GSK group of companies.

©2022 GSK Group of Companies or its licensor.

10661 | 06/23